← All trials
NCT05332340
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 16, 2022
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Apr 18, 2022
- Last posted
- Nov 23, 2022
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biozeus Biopharmaceutical S.A.Lead sponsor
- AzidusCollaborator
- AzidusOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.